Ningbo EIT Digital Biotechnology Co., Ltd.
The Yinzhou (Dongfang University of Science and Technology) Digital and Intelligent Biotechnology Innovation Institute was established in February 2025. As a new type of R&D institution receiving key support from Yinzhou District, Ningbo City, it is led by Professor Jin Dayong, a Fellow of the Australian Academy of Engineering, who serves as its Director and Chief Scientist. The institute is jointly developed by Ningbo Dongfang University of Science and Technology and the Zhejiang Provincial Engineering Research Center for Organelle-Targeted Precision Diagnosis and Treatment. Distinguished by its integration of medicine and engineering, digital and intelligent empowerment, and the commercialization of research outcomes, the Institute is committed to promoting the deep integration of artificial intelligence and biomedicine, and to building an innovation platform that integrates applied R&D, proof of concept, technical services, talent development, and industrial collaboration.
Addressing major needs in the field of life sciences and health, the Institute focuses on areas such as organelle functional imaging and precision diagnosis and treatment, novel rapid antibiotic susceptibility testing, R&D of high-end digital and intelligent bioimaging instruments, nanomedicine delivery and screening, biomedical artificial intelligence, and AI-powered virtual cells. Leveraging the research expertise of the Organelle-Based Precision Diagnostics and Treatment (ODT) team in biophotonics, biomedical diagnostics, and high-end instrumentation engineering, the Institute integrates technologies such as subcellular phenotypic imaging, cross-scale imaging, automated detection, and intelligent analysis to advance the translation of scientific research outcomes into clinical validation and industrial applications.
Among its representative achievements, the team has developed the HAPA rapid antibiotic susceptibility testing platform, which integrates bacterial subcellular phenotypic imaging, automated detection, and intelligent analysis. By monitoring subcellular phenotypic changes at the single-cell level under the action of antibiotics, the platform achieves a testing process that takes approximately 4 hours from bacterial inoculation to the issuance of the susceptibility report. This platform, which holds independent intellectual property rights, is designed for applications such as clinical microbiological testing, anti-infective research, and drug screening. It has undergone testing with clinically isolated bacteria and validation through hospital collaborations, and the team continues to advance the engineering of the equipment and product development.
The Institute has been approved as a Zhejiang Provincial Postdoctoral Workstation. Leveraging its multi-tiered scientific research and engineering R&D teams, it actively recruits and cultivates high-level talent and promotes scientific research practices, while deepening cooperation with universities, research institutions, medical institutions, and life sciences and healthcare enterprises. Focusing on fields such as high-end instrumentation, biopharmaceuticals, and artificial intelligence, the Institute provides technical and talent support to partners through joint laboratories, collaborative technical research, application validation, technology licensing, and technology transfer, thereby fostering the innovative development of the regional life sciences and healthcare industry.
